SCHEMBL6508928

SCHEMBL6508928

CCN(CCCNC(=O)CCc1ccccc1)Cc1cccc(Oc2ccccc2OC)c1

nearest known ligand 0.62

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.62
BCHE P06276 1/20 0.48
POLB P06746 1/20 0.48
KDM4E B2RXH2 2/20 0.48
LMNA P02545 1/20 0.47
APP P05067 2/20 0.47
ACHE P22303 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500080 0.91 CCR8 (0.50) GAABCHEKDM4ELMNAAPP
SCHEMBL6501980 0.90 GAA (0.69) GAABCHEPOLBKDM4ELMNA
SCHEMBL6498806 0.88 ACHE (0.50) BCHEKDM4EAPPACHE
SCHEMBL6496812 0.86 BCHE (0.55) BCHEPOLBLMNAAPPACHE
SCHEMBL6499418 0.85 APP (0.46) BCHEAPPACHE
SCHEMBL6503409 0.84 MCHR1 (0.47) BCHEAPPACHE
SCHEMBL6500610 0.84 GAA (0.59) GAABCHEKDM4ELMNAHPGD
SCHEMBL6498983 0.84 APP (0.49) POLBAPPACHE
SCHEMBL6506745 0.84 ATM (0.48) POLBKDM4EAPPACHEHPGD
SCHEMBL6505243 0.83 ACHE (0.51) GAAAPPACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2005-06-30 US disclosed
WO-2003037271-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS,INC. (US) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor CCR8, CCL11, CCR5 GAA 2177/4885BCHE 945/4885POLB 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.